Evidence map›Paper›PMID 28790893›Full record

ReviewFrontiers in cellular neuroscience2017

Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration.

Duraisamy Kempuraj, Ramasamy Thangavel, Govindhasamy P Selvakumar, Smita Zaheer, Mohammad E Ahmed, Sudhanshu P Raikwar, Haris Zahoor, Daniyal Saeed, Prashant A Natteru, Shankar Iyer and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in cellular neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 204 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
204citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

204 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Herbal medicines for SOD1Frontiers in immunology · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

144 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Duraisamy KempurajHarry S. Truman Memorial Veteran's Hospital, U.S. Department of Veterans AffairsColumbia, MO, United States.
Ramasamy ThangavelHarry S. Truman Memorial Veteran's Hospital, U.S. Department of Veterans AffairsColumbia, MO, United States.
Govindhasamy P SelvakumarHarry S. Truman Memorial Veteran's Hospital, U.S. Department of Veterans AffairsColumbia, MO, United States.
Smita ZaheerDepartment of Neurology and the Center for Translational Neuroscience, School of Medicine, University of MissouriColumbia, MO, United States.
Mohammad E AhmedDepartment of Neurology and the Center for Translational Neuroscience, School of Medicine, University of MissouriColumbia, MO, United States.
Sudhanshu P RaikwarHarry S. Truman Memorial Veteran's Hospital, U.S. Department of Veterans AffairsColumbia, MO, United States.
Haris ZahoorDepartment of Neurology and the Center for Translational Neuroscience, School of Medicine, University of MissouriColumbia, MO, United States.
Daniyal SaeedDepartment of Neurology and the Center for Translational Neuroscience, School of Medicine, University of MissouriColumbia, MO, United States.
Prashant A NatteruDepartment of Neurology and the Center for Translational Neuroscience, School of Medicine, University of MissouriColumbia, MO, United States.
Shankar IyerHarry S. Truman Memorial Veteran's Hospital, U.S. Department of Veterans AffairsColumbia, MO, United States.
Asgar ZaheerHarry S. Truman Memorial Veteran's Hospital, U.S. Department of Veterans AffairsColumbia, MO, United States.

Funding

GMF-dependent neuroinflammation and neurodegenerationR01NS073670 · NINDS · UNIVERSITY OF MISSOURI-COLUMBIA · PI ZAHEER, ASGAR · 2011 to 2015
$1.6M
Therapeutic potential of GMF suppresssion in inflammation and neurodegenerationR01AG048205 · NIA · UNIVERSITY OF MISSOURI-COLUMBIA · PI ZAHEER, ASGAR · 2015 to 2019
$1.6M
Glia maturation factor dependent mast cell activation in Parkinson's diseaseI01BX002477 · VA · IOWA CITY VA MEDICAL CENTER · PI ZAHEER, ASGAR · 2015 to 2017
–
BLRD VA I01 BX002477NIA NIH HHS R01 AG048205NINDS NIH HHS R01 NS073670
6 · The paper itself

Abstract

Neuroinflammatory response is primarily a protective mechanism in the brain. However, excessive and chronic inflammatory responses can lead to deleterious effects involving immune cells, brain cells and signaling molecules. Neuroinflammation induces and accelerates pathogenesis of Parkinson's disease (PD), Alzheimer's disease (AD) and Multiple sclerosis (MS). Neuroinflammatory pathways are indicated as novel therapeutic targets for these diseases. Mast cells are immune cells of hematopoietic origin that regulate inflammation and upon activation release many proinflammatory mediators in systemic and central nervous system (CNS) inflammatory conditions. In addition, inflammatory mediators released from activated glial cells induce neurodegeneration in the brain. Systemic inflammation-derived proinflammatory cytokines/chemokines and other factors cause a breach in the blood brain-barrier (BBB) thereby allowing for the entry of immune/inflammatory cells including mast cell progenitors, mast cells and proinflammatory cytokines and chemokines into the brain. These peripheral-derived factors and intrinsically generated cytokines/chemokines, α-synuclein, corticotropin-releasing hormone (CRH), substance P (SP), beta amyloid 1-42 (Aβ1-42) peptide and amyloid precursor proteins can activate glial cells, T-cells and mast cells in the brain can induce additional release of inflammatory and neurotoxic molecules contributing to chronic neuroinflammation and neuronal death. The glia maturation factor (GMF), a proinflammatory protein discovered in our laboratory released from glia, activates mast cells to release inflammatory cytokines and chemokines. Chronic increase in the proinflammatory mediators induces neurotoxic Aβ and plaque formation in AD brains and neurodegeneration in PD brains. Glial cells, mast cells and T-cells can reactivate each other in neuroinflammatory conditions in the brain and augment neuroinflammation. Further, inflammatory mediators from the brain can also enter into the peripheral system through defective BBB, recruit immune cells into the brain, and exacerbate neuroinflammation. We suggest that mast cell-associated inflammatory mediators from systemic inflammation and brain could augment neuroinflammation and neurodegeneration in the brain. This review article addresses the role of some atypical inflammatory mediators that are associated with mast cell inflammation and their activation of glial cells to induce neurodegeneration.

Indexed as

braincytokines and chemokinesinflammatory mediatorsmast cellsneurodegenerative diseasesneuroinflammation

Identifiers

PMID28790893
PMCPMC5522882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.